Yes, Teriparatide Can Cause Headaches
Headache is a documented adverse effect of subcutaneous teriparatide injection, occurring in 7.5% of treated patients compared to 7.4% in placebo-treated patients in clinical trials 1. While the incidence is only marginally higher than placebo, headaches are specifically listed as a recognized adverse event in the FDA drug label.
Clinical Evidence from Trials
In the two principal osteoporosis trials involving 1,382 patients (691 receiving teriparatide, 691 receiving placebo), headache was reported among adverse events occurring in ≥2% of teriparatide-treated patients 1. The near-equivalent rates between treatment and placebo groups (7.5% vs 7.4%) suggest that while headaches do occur, they may not be strongly causally related to the medication itself.
Context of Other Adverse Effects
Headaches should be considered within the broader adverse event profile of teriparatide:
- More common adverse effects include pain (21.3%), nausea (8.5%), dizziness (8.0%), and asthenia/weakness (8.7%) 1
- Orthostatic hypotension is a notable concern, occurring in approximately 5% of patients, typically within 4 hours of dosing 1
- In overdose situations, headache is specifically mentioned as a potential complication alongside dizziness and vomiting 1
Important Clinical Considerations
Monitor for orthostatic symptoms: Since teriparatide can cause transient orthostatic hypotension (particularly in the first several doses), headaches occurring within 4 hours of injection may be related to blood pressure changes rather than direct drug effect 1. Initial doses should be administered where patients can sit or lie down if needed.
Timing matters: The transient nature of many teriparatide side effects means headaches occurring shortly after injection may resolve spontaneously within hours 2.
Calcium-related effects: Teriparatide transiently increases serum calcium 4-6 hours post-dose, which theoretically could contribute to headache symptoms 1.
Practical Management
If headaches occur with teriparatide:
- Assess timing relative to injection (immediate vs delayed)
- Check for associated orthostatic symptoms
- Consider measuring serum calcium if headaches are persistent
- Ensure adequate hydration
- Most transient side effects improve with continued treatment
The overall discontinuation rate due to adverse events was only 7% for teriparatide versus 6% for placebo, indicating most side effects including headaches are generally tolerable 1.